

### ICARUS-IBD Updates:

The first round of serological testing involving 2241 patients' pre vaccination has been completed and the preliminary analysis has been circulated. Abstracts have been submitted to the annual meetings of ECCO and AGA.

The data are of great interest and highlight the associations between seropositivity and geographical location; as well as with immune-suppression, disease type, and smoking habit.

Of particular note is the contrast between data from India, Hong Kong and Western Europe and North America.



The ICARUS Team would like to wish you a **Merry Christmas** and a **Happy New Year!**

Thank you for all your kind support and contribution to the study so far, we are making fantastic progress and very excited for what will come in 2022!

### Next Phase:

The emphasis for the next phase is to assess serological responses to both infection, and vaccination across the centres – with particular interest in the effects of medications, geography, vaccination strategy (type of vaccine, effect of booster doses). These are areas in which this study is uniquely well placed to deliver original data.

We aim to deliver deeper immunological and serological analysis including in-depth analysis of serological and neutralization responses to specific SARS-CoV-2 variants (alpha, delta, and newly emerging variants, since experimental set-up is flexible in design).

These aims are supported by re-allocating the funding provided and by requesting an extension to complete this exciting program and gain full benefit from ICARUS-IBD.

### Site recruitment as of 17/12/21.

